本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、截至 2025 年 10 月 21 日，蓝帆医疗股份有限公司（以下简称"公司"）股价 已出现连续三十个交易日中至少有十五个交易日的收盘价低于当期转股价格 85%的情 形，已触发"蓝帆转债"转股价格向下修正条件。 2、经公司第六届董事会第三十一次会议审议通过，公司董事会提议向下修正 "蓝帆转债"转股价格。 | 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-085 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于董事会提议向下修正"蓝帆转债"转股价格的公告 3、本次向下修正"蓝帆转债"转股价格的提议尚需提交公司股东会审议。 一、可转债发行上市基本情况 （一）可转债发行情况 经中国证券监督管理委员会"证监许可〔2020〕710 号"文核准，公司于 2020 年 5 月 28 日公开发行了3,144.04 万张可转换公司债券（以下简称"可转债"），每张面值100 元，发 行总额314,404 万元。 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于召开2025年第五次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 经蓝帆医疗股份有限公司（以下简称"公司"或"本公司"）第六届董事会第三 十一次会议审议通过，公司决定于 2025 年 11 月 7 日召开 2025 年第五次临时股东会， 现将有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第五次临时股东会 2、股东会的召集人：董事会 3、会议召开的合法、合规性：本次召开股东会的议案经公司第六届董事会第三 十一次会议审议通过。本次股东会的召集、召开符合《中华人民共和国公司法》《深 圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《蓝帆医疗股 份有限公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-084 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 一、董事会会议召开情况 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第三十一次会议于 2025 年 10 月 17 日以电子邮件的方式发出通知，于 2025 年 10 月 21 日以通讯表决的方式召 开。本次会议应参加会议董事 8 人，实际参加会议董事 8 人，全体董事以通讯的方式 出席会议。公司董事长刘文静女士主持了本次会议。会议的通知、召开、表决程序符 合《中华人民共和国公司法》和《蓝帆医疗股份有限公司章程》的规定。 二、董事会会议审议情况 1、审议并通过了《关于董事会提议向下修正"蓝帆转债"转股价格的议案》； 截至2025年10月21日，公司股票已出现连续三十个交易日中至少有十五个交易日 的收盘价低于当期转股价格85%的情形，已触发"蓝帆转债"转股价格向下修正条件。 为充分保护债券持有人利益，优化公司资本结构，支持公司长期发展，董事会提 议向下修正"蓝帆转债"转股价格，该提议尚需提交公司股东会审议。修正后的转股 ...

Core Viewpoint - Bluefan Medical (002382) has shown a mixed performance in recent trading, with a slight increase in stock price but a significant decline in financial metrics, indicating potential challenges ahead for the company [1][3]. Financial Performance - As of October 20, 2025, Bluefan Medical's stock closed at 5.68 yuan, up 3.27% with a trading volume of 156,500 shares and a total transaction value of 88.86 million yuan [1]. - The company reported a main operating revenue of 2.781 billion yuan for the first half of 2025, a year-on-year decrease of 7.49% [3]. - The net profit attributable to shareholders was -135 million yuan, which represents a year-on-year increase of 15.88% [3]. - The second quarter of 2025 saw a significant decline in performance, with a single-quarter main operating revenue of 1.303 billion yuan, down 16.0% year-on-year, and a net profit of -212 million yuan, a decrease of 245.53% [3]. Market Position and Ratios - Bluefan Medical's total market capitalization is 5.721 billion yuan, ranking 62nd in the medical device industry, which has an average market cap of 11.662 billion yuan [3]. - The company has a price-to-earnings ratio (P/E) of -21.22, compared to the industry average of 65.67, indicating a challenging earnings environment [3]. - The company's price-to-book ratio (P/B) stands at 0.73, significantly lower than the industry average of 3.77, suggesting undervaluation relative to its book value [3]. - Bluefan Medical's gross margin is 14.34%, which is considerably lower than the industry average of 51.83%, reflecting operational inefficiencies [3]. Capital Flow Analysis - On October 20, 2025, the net inflow of main funds was 9.7742 million yuan, accounting for 11.0% of the total transaction value, while retail investors saw a net outflow of 14.9712 million yuan, representing 16.85% of the total [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net inflows and outflows from both institutional and retail investors [2].

Core Insights - Bluefan Medical's stock price decreased by 0.36% on October 16, with a trading volume of 38.92 million yuan [1] - The company reported a financing net purchase of 1.34 million yuan on the same day, with a total financing and securities balance of 337 million yuan [1][2] - The company's main business revenue composition includes 70.08% from health protection products, 24.88% from cardiovascular products, and 3.72% from emergency rescue products [1] Financing and Securities - On October 16, Bluefan Medical had a financing buy amount of 5.34 million yuan, with a current financing balance of 337 million yuan, representing 5.99% of its market capitalization [1] - The financing balance is above the 80th percentile level over the past year, indicating a high level of financing activity [1] - The company had a securities lending balance of 570,300 yuan, with a lending volume of 102,200 shares on the same day [1] Shareholder and Financial Performance - As of September 19, the number of shareholders for Bluefan Medical was 74,800, a decrease of 5.19% from the previous period [2] - The average circulating shares per person increased by 5.48% to 13,363 shares [2] - For the first half of 2025, the company reported a revenue of 2.781 billion yuan, a year-on-year decrease of 7.49%, while the net profit attributable to shareholders was -135 million yuan, a year-on-year increase of 15.88% [2] Dividend and Institutional Holdings - Bluefan Medical has distributed a total of 1.348 billion yuan in dividends since its A-share listing, with 403 million yuan distributed in the last three years [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 16.8348 million shares, an increase of 1.1296 million shares from the previous period [3]

Group 1 - The core point of the article is that 蓝帆医疗 (Blue Sail Medical) is expected to trigger a downward adjustment of its convertible bond conversion price due to its stock price being below the threshold for 10 consecutive trading days [1][3] - As of October 15, 2025, the stock price closed at 5.6 yuan, with a trading volume of 67,000 hands and a turnover of 37.49 million yuan [1] - The current conversion price for the convertible bond is 10.50 yuan per share, and the stock price has been below 85% of this price (8.925 yuan) for the required period [1][3] Group 2 - On October 15, 2025, the net inflow of main funds was 197,300 yuan, while retail investors also showed a net inflow of 410,700 yuan; however, speculative funds experienced a net outflow of 608,100 yuan [1][3] - The company has a history of adjusting the conversion price of its convertible bonds, with the most recent adjustments occurring on various dates, leading to the current price of 10.50 yuan per share [1]

Core Insights - Foxconn's chairman recently met with OpenAI's CEO Sam Altman to discuss potential future collaborations [1] Group 1 - The meeting indicates a strategic interest from Foxconn in exploring partnerships with AI technology leaders [1] - OpenAI's advancements in artificial intelligence may align with Foxconn's manufacturing and technology goals [1]

Core Viewpoint - Foxconn's acquisition of a subsidiary of ZF Group in Germany is currently stalled [1] Company Summary - The transaction involving Foxconn and ZF Group's subsidiary has encountered delays, impacting the expected timeline for completion [1]

Group 1 - The core point of the article indicates that BluFan Medical (002382) is expected to trigger a downward adjustment of its convertible bond conversion price due to its stock price being below 85% of the current conversion price for 10 consecutive trading days [1][3] - As of October 14, 2025, BluFan Medical's stock closed at 5.6 yuan, reflecting a 1.45% increase with a trading volume of 92,800 shares and a transaction amount of 51.79 million yuan [1] - The main capital flow on October 14 shows a net inflow of 2.785 million yuan from institutional investors, while retail investors experienced a net outflow of 729,700 yuan [1][3] Group 2 - The current conversion price for the convertible bond is 10.50 yuan per share, and if the adjustment condition is triggered, the company will hold a board meeting to discuss whether to revise the conversion price [1] - Historical adjustments of the conversion price have occurred multiple times, with the latest being 10.50 yuan per share as of September 23, 2025, down from previous prices [1]

Core Viewpoint - The company, BluFan Medical Co., Ltd., is expected to trigger the condition for a downward adjustment of the convertible bond conversion price due to its stock price being below 85% of the current conversion price for 10 trading days [2][12]. Group 1: Convertible Bond Issuance and Adjustment - The company issued 31,440,404 convertible bonds with a total value of 314.404 million yuan on May 28, 2020 [3]. - The convertible bonds were listed on the Shenzhen Stock Exchange on June 19, 2020, under the name "BluFan Convertible Bond" and code "128108" [4]. - The conversion period for the bonds is from December 3, 2020, to May 27, 2026 [5]. - The initial conversion price was set at 10.50 yuan per share [2]. Group 2: Conversion Price Adjustments - The conversion price has been adjusted multiple times due to various corporate actions, including performance compensation and profit distribution [6][7][8]. - The conversion price was adjusted from 17.79 yuan to 18.64 yuan on June 25, 2021, and subsequently to 18.24 yuan on July 7, 2021, and further to 17.84 yuan on May 31, 2023 [6][7][8]. - The most recent adjustment occurred on September 23, 2025, lowering the conversion price to 10.50 yuan per share [10]. Group 3: Trigger Conditions for Price Adjustment - The company is required to hold a board meeting to decide on the adjustment of the conversion price if the stock price remains below 85% of the conversion price for 10 trading days [12]. - The specific threshold for triggering the adjustment is set at 8.925 yuan per share, which is 85% of the current conversion price of 10.50 yuan [12].